FDA-approved Treatments
Experimental Treatments
Top New Articles
 Google Custom Search

Federal Government Announces $1.1 Billion in Ryan White Grants for HIV/AIDS Services

On April 8, the U.S. Department of Health and Human Service (DHHS) announced a new round of grants to states and territories for HIV/AIDS care and services under Part B of the Ryan White HIV/AIDS Program, which includes AIDS Drug Assistance Programs (ADAPs).

Below is the text of the recent DHHS news release:

HHS Awards $1.1 Billion for
HIV/AIDS Care, Medications

HHS Secretary Mike Leavitt has announced grants of more than $1.1 billion to provide primary care, medications, and services for low-income and underinsured people living with HIV/AIDS.

Funded under Part B of the Ryan White HIV/AIDS Program, the grants are awarded to all 50 states, the District of Columbia, Puerto Rico, Guam, and the U.S. Virgin Islands. Also receiving grants are the U.S. Pacific Territories of American Samoa and Commonwealth of the Northern Mariana Islands; and the Associated Jurisdictions of the Republic of the Marshall Islands, Federated States of Micronesia, and Republic of Palau. HHS' Health Resources and Services Administration (HRSA) manages the Ryan White program.

"These Ryan White HIV/AIDS Part B grants help ensure Americans, especially those in rural and underserved communities, affected by HIV/AIDS get access to the care they need through quality health care and support systems," Secretary Leavitt said. "These grants strengthen community, city and state capacities to care for those with HIV."

The majority of the funding, $774 million, supports state AIDS Drug Assistance Programs (ADAPs) that provide prescription medications for HIV/AIDS patients. In 2006, close to 158,000 ADAP clients were served through state ADAPs.

Part B awards also include formula base grants that can be used for home and community-based services, insurance continuation, ADAP assistance, and other direct services. Fourteen states will also receive Emerging Community (EC) grants based on the number of AIDS cases over the most recent 5-year period.

"Ryan White Part B awards reflect the urgent need for life-saving medications for those living with HIV/AIDS," said HRSA Administrator Elizabeth Duke. "Today we are thankful and proud that all ADAP waiting lists have been eliminated."

Every year, the Ryan White HIV/AIDS Program helps more than 530,000 people access the care and services they need to live longer, healthier lives. Information on all domestic, Federal HIV/AIDS programs is available at www.aids.gov.

HRSA, part of the U. S. Department of Health and Human Services, is the primary federal agency for improving access to health care services for people who are uninsured, isolated, or medically vulnerable. For more information about HRSA and its programs, visit www.hrsa.gov.

For a listing of specific amounts awarded to each state and territory, see: www.os.dhhs.gov/news/press/2008pres/04/20080404a.html.

4/11/08

Source
U.S. Department of Health and Human Services. HHS Awards $1.1 Billion for HIV/AIDS Care, Medications. News release. April 4, 2008.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protease Inhibitors (PIs)
Note: Most PIs are now used
in combination with low-dose
ritonavir (Norvir)
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir )
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
Viracept
Viracept (nelfinavir)
Nucleoside / Nucleotide
Reverse Transcriptase
Inhibitors (NRTIs)
Combivir
Combivir (zidovudine + lamivudine)
Epivir
Epivir (lamivudine; 3TC)
Emtriva
Emtriva (emtricitabine; FTC)
Epzicom
Epzicom (abacavir + lamivudine)
Retrovir
Retrovir (zidovudine; AZT)
Trizivir
Trizivir (abacavir + zidovudine +lamivudine)
Truvada
Truvada  (tenofovir + emtricitabine)
Videx
Videx (didanosine; ddI)
Viread
Viread (tenofovir)
Zerit
Zerit (stavudine; d4T)
Ziagen
Ziagen (abacavir)
non Nucleoside 
Reverse Transcriptase
 Inhibitors
(nNRTIs)
Rescriptor
Intelence (etravirine)
Rescriptor
Rescriptor (delavirdine)
Sustiva
Sustiva (efavirenz)
Viramune
Viramune (nevirapine)
Entry / Fusion Inhibitors
Fuzeon (enfuvirtide)
Selzentry/Celsentri ( maraviroc)
Fixed-dose Combinations
Atripla
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir
Combivir (zidovudine + lamivudine)
Trizivir
Trizivir (abacavir + zidovudine + lamivudine)
Truvada
Truvada (tenofovir + emtricitabine)
Integrase Inhibitors
Isentress (raltegravir)